News Quantified

FOLD – amicus therapeutics, inc. (US:NASDAQ)

Stock Stats

News Stats

Order Stats

News

Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus [Yahoo! Finance]

Amicus Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]

Amicus Therapeutics Announces Full-Year 2025 Financial Results and Corporate Updates

TD Cowen Cautious on Amicus Therapeutics (FOLD) Despite Positive 2025 Revenue Projections [Yahoo! Finance]

Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments [Yahoo! Finance]

0.1%

BEAT

-1.2%

BEAT

-6.4%

BEAT

-9.7%

BEAT

Form 4 AMICUS THERAPEUTICS, For: Mar 02 Filed by: Campbell Bradley L

Form 8-K AMICUS THERAPEUTICS, For: Mar 03

Form 144 AMICUS THERAPEUTICS, Filed by: Campbell Bradley L

Form DEFA14A AMICUS THERAPEUTICS,

Form 10-K AMICUS THERAPEUTICS, For: Dec 31

Top News Gainers

4/2 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was downgraded by analysts at BidaskClub from a "buy" rating to a "hold" rating. 8.5%

2/4 Amicus Therapeutics, Inc. (NASDAQ: FOLD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $20.00 price target on the stock, up previously from $19.00. 7.0%

3/9 Form 4 AMICUS THERAPEUTICS, For: Mar 05 Filed by: Campbell Bradley L 6.9%

2/4 Form 4 AMICUS THERAPEUTICS, For: Jan 31 Filed by: Crowley John F 6.5%

6/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) is now covered by analysts at HC Wainwright. They set a "buy" rating on the stock. 5.8%

1/14 Form 4 AMICUS THERAPEUTICS, For: Jan 10 Filed by: Barth Jay 5.4%

10/3 Is Amicus Therapeutics, Inc. (NASDAQ:FOLD) A Volatile Stock? [Yahoo! Finance News] 4.8%

3/24 Form 4 AMICUS THERAPEUTICS, For: Mar 20 Filed by: Crowley John F 4.4%

7/17 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was given a new $18.00 price target on by analysts at HC Wainwright. They now have a "buy" rating on the stock. 4.4%

4/24 Amicus Therapeutics to Announce First Quarter 2020 Financial Results on May 7, 2020 4.3%

Top News Decliners

10/3 Amicus snaps back on positive data from Pompe Disease study of AT-GAA [Seeking Alpha] -10.0%

8/2 Amicus Therapeutics Receives Marketing Authorization for Galafold® (migalastat) for Fabry Disease in Argentina -9.0%

3/2 Amicus Therapeutics Announces Full-Year 2019 Financial Results and 2020 Corporate Updates -8.4%

8/8 Amicus Therapeutics, Inc. (FOLD) CEO John Crowley on Q2 2019 Results - Earnings Call Transcript [Seeking Alpha] -7.5%

5/29 Amicus Therapeutics Announces Public Offering of Common Stock -7.2%

12/4 Form 4 AMICUS THERAPEUTICS, For: Dec 02 Filed by: Crowley John F -6.8%

8/8 Q2/2019 6/30/2019 EPS -0.360 ZacksConsensus -0.340 ActVsEst (0.020) - Miss -6.7%

7/4 Why Amicus Therapeutics' Stock Perked Up in June [The Motley Fool] -6.2%

1/18 Amicus Therapeutics, Inc. (NASDAQ: FOLD) was upgraded by analysts at BidaskClub from a "hold" rating to a "buy" rating. -6.0%

1/13 Form 8-K AMICUS THERAPEUTICS, For: Jan 13 -5.7%

Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies

If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview

Earnings Week Wrap-up and Takeaways

Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix

Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More

The Smart Way to Ten Minutes Per Day